Evidence map›Paper›PMID 41436432›Full record

ReviewCell death & disease2025

Gasdermins in neurodegeneration: emerging mechanisms and therapeutic targets.

Sizhuo Chen, Jing Zhang, Xin Chen, Zhongmeng Lai, Zhenhuan Zhao, Shao-Bin Wang

Abstract readReview
In one paragraph

Review in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sizhuo ChenNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.
Jing ZhangCenter for Advanced Vision Science, University of Virginia, Charlottesville, VA, USA.
Xin ChenNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China.
Zhongmeng LaiDepartment of Anesthesiology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. zl7mg@fjmu.edu.cn.
Zhenhuan ZhaoNational "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Hubei University of Technology, Wuhan, China. zhaozhenhuan@hbut.edu.cn.ORCID http://orcid.org/0000-0002-6305-8037
Shao-Bin WangCenter for Advanced Vision Science, University of Virginia, Charlottesville, VA, USA. sw3ta@virginia.edu.ORCID http://orcid.org/0000-0002-6699-9406

Funding

Defining the role of SINE retrotransposons and inflammasome activation in Alzheimer's diseaseR01AG078892 · NIA · UNIVERSITY OF VIRGINIA · PI Jayakrishna Ambati, Bradley David Gelfand · 2022 to 2026
$3.1M
Cytosolic SINE retrotransposable element cDNA and mitochondrial DNA in aging retinaR01AG082748 · NIA · UNIVERSITY OF VIRGINIA · PI Jayakrishna Ambati, Bradley David Gelfand · 2023 to 2026
$2.5M
Boehringer Ingelheim (Boehringer Ingelheim Pharmaceuticals) 918100Department of Science and Technology, Hubei Provincial People's Government (Hubei Provincial Department of Science and Technology) 2025AFA017Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01AG078892Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01AG082748Fujian Provincial Department of Science and Technology (Department of Science and Technology of Fujian Province) 2021Y9073Fujian Provincial Department of Science and Technology (Department of Science and Technology of Fujian Province) FJHCHR202326Hubei University of Technology (HBUT) GCC2024015Hubei University of Technology (HBUT) XJ2024000201Hubei University of Technology (HBUT) XJ2024004402National Natural Science Foundation of China (National Science Foundation of China) 32300783National Natural Science Foundation of China (National Science Foundation of China) 82171201Natural Science Foundation of Fujian Province (Fujian Provincial Natural Science Foundation) 2023ZQNZD003Natural Science Foundation of Fujian Province (Fujian Provincial Natural Science Foundation) FJHRSS2022173NIA NIH HHS R01 AG078892NIA NIH HHS R01 AG082748
6 · The paper itself

Abstract

Gasdermins (GSDM) are pore-forming proteins that mediate pyroptosis, an inflammatory form of programmed cell death characterized by membrane permeabilization and the release of intracellular contents. Beyond their roles in host defense and immunity, recent studies have revealed critical contributions of GSDMs, particularly GSDMD and GSDME, to the pathogenesis of neurodegenerative disorders. Their functional scope has now expanded beyond executing cell death to roles in tissue regeneration and food tolerance. The recent discovery that intact, full-length GSDMs can form pores is prompting a reevaluation of long-standing models of gasdermin activation. How post-transcriptional modifications (PTMs) regulate this unconventional activity, and under what physiological or pathological contexts these alternative mechanisms are engaged, remains an open question. Moreover, the development of neutralizing biologics that specifically target GSDM pores opens new avenues for therapeutic intervention. In light of these emerging insights, this review will provide a comprehensive and up-to-date overview of recent breakthroughs in GSDM research. We highlight advances in the structural basis of GSDM activation and pore assembly. We also discuss how these mechanisms are involved in the pathogenesis of neurodegenerative diseases and therapeutic strategies based on the emerging small-molecule inhibitors and neutralizing biologics.

Indexed as

Neurodegenerative DiseasesAnimalsGasderminsHumansPyroptosisGasdermins

Identifiers

PMID41436432
PMCPMC12847837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.